These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1000 related articles for article (PubMed ID: 27069084)

  • 21. JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy.
    Gupta S; Vanderbilt CM; Cotzia P; Arias Stella JA; Chang JC; Chen Y; Tang LH; DeLair DF; Yao J; Ladanyi M; Ross DS
    Hum Pathol; 2019 Jun; 88():87-91. PubMed ID: 30236595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.
    Goodman AM; Piccioni D; Kato S; Boichard A; Wang HY; Frampton G; Lippman SM; Connelly C; Fabrizio D; Miller V; Sicklick JK; Kurzrock R
    JAMA Oncol; 2018 Sep; 4(9):1237-1244. PubMed ID: 29902298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management.
    Gupta S; Cheville JC; Jungbluth AA; Zhang Y; Zhang L; Chen YB; Tickoo SK; Fine SW; Gopalan A; Al-Ahmadie HA; Sirintrapun SJ; Blum KA; Lohse CM; Hakimi AA; Thompson RH; Leibovich BC; Berger MF; Arcila ME; Ross DS; Ladanyi M; Antonescu CR; Reuter VE
    Mod Pathol; 2019 Sep; 32(9):1344-1358. PubMed ID: 30996253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Stanford V regimen is effective in patients with good risk Hodgkin lymphoma but radiotherapy is a necessary component.
    Abuzetun JY; Loberiza F; Vose J; Bierman P; Bociek RG; Enke C; Bast M; Weisenburger D; Armitage JO;
    Br J Haematol; 2009 Feb; 144(4):531-7. PubMed ID: 19055670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nivolumab in the Treatment of Hodgkin Lymphoma.
    Ansell SM
    Clin Cancer Res; 2017 Apr; 23(7):1623-1626. PubMed ID: 27881581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
    Chen M; Pockaj B; Andreozzi M; Barrett MT; Krishna S; Eaton S; Niu R; Anderson KS
    Clin Breast Cancer; 2018 Oct; 18(5):e1205-e1215. PubMed ID: 29933930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification.
    Chen M; Andreozzi M; Pockaj B; Barrett MT; Ocal IT; McCullough AE; Linnaus ME; Chang JM; Yearley JH; Annamalai L; Anderson KS
    Mod Pathol; 2017 Nov; 30(11):1516-1526. PubMed ID: 28752839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
    Rotman J; den Otter LAS; Bleeker MCG; Samuels SS; Heeren AM; Roemer MGM; Kenter GG; Zijlmans HJMAA; van Trommel NE; de Gruijl TD; Jordanova ES
    Front Immunol; 2020; 11():596825. PubMed ID: 33424844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic Amplification of
    George J; Saito M; Tsuta K; Iwakawa R; Shiraishi K; Scheel AH; Uchida S; Watanabe SI; Nishikawa R; Noguchi M; Peifer M; Jang SJ; Petersen I; Büttner R; Harris CC; Yokota J; Thomas RK; Kohno T
    Clin Cancer Res; 2017 Mar; 23(5):1220-1226. PubMed ID: 27620277
    [No Abstract]   [Full Text] [Related]  

  • 30. Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma.
    Jain MD; Kuruvilla J
    Drugs; 2017 Oct; 77(15):1645-1655. PubMed ID: 28819821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 Status in Refractory Lymphomas.
    Vranic S; Ghosh N; Kimbrough J; Bilalovic N; Bender R; Arguello D; Veloso Y; Dizdarevic A; Gatalica Z
    PLoS One; 2016; 11(11):e0166266. PubMed ID: 27861596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
    Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
    N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.
    Barrett MT; Anderson KS; Lenkiewicz E; Andreozzi M; Cunliffe HE; Klassen CL; Dueck AC; McCullough AE; Reddy SK; Ramanathan RK; Northfelt DW; Pockaj BA
    Oncotarget; 2015 Sep; 6(28):26483-93. PubMed ID: 26317899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
    Sasse S; Bröckelmann PJ; Goergen H; Plütschow A; Müller H; Kreissl S; Buerkle C; Borchmann S; Fuchs M; Borchmann P; Diehl V; Engert A
    J Clin Oncol; 2017 Jun; 35(18):1999-2007. PubMed ID: 28418763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management.
    Gupta S; Vanderbilt CM; Cotzia P; Arias-Stella JA; Chang JC; Zehir A; Benayed R; Nafa K; Razavi P; Hyman DM; Baselga J; Berger MF; Ladanyi M; Arcila ME; Ross DS
    J Mol Diagn; 2019 Mar; 21(2):307-317. PubMed ID: 30576871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous-cell and adenocarcinoma patients.
    Clavé S; Pijuan L; Casadevall D; Taus Á; Gimeno J; Hernández-Llodrà S; Rodríguez-Rivera M; Lorenzo M; Menéndez S; Albanell J; Espinet B; Arriola E; Salido M
    Histopathology; 2018 Jan; 72(2):259-269. PubMed ID: 28795418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 9p24.1 Genetic Alteration and PD-L1 Expression Are Characteristic of De Novo and Methotrexate-associated Epstein-Barr Virus-positive Hodgkin Lymphoma, But Not Methotrexate-associated Hodgkin-like Lesions.
    Shiraiwa S; Kikuti YY; Carreras J; Kondo Y; Ohmachi K; Ogawa Y; Kawada H; Sato S; Gion Y; Sato Y; Nakamura N; Ando K
    Am J Surg Pathol; 2022 Aug; 46(8):1017-1024. PubMed ID: 35848760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 and PD-L2 Mutations in Pediatric Hodgkin Lymphoma: Do They Have Any Prognostic Significance?
    Gül G; Ince D; Olgun N; Ozer E
    Fetal Pediatr Pathol; 2022 Feb; 41(1):49-57. PubMed ID: 32401663
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.
    Menter T; Bodmer-Haecki A; Dirnhofer S; Tzankov A
    Hum Pathol; 2016 Aug; 54():17-24. PubMed ID: 27045512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.